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“Molecular neurosurgery” is emerging as a new medical concept, and is the combination
of two partners: (i) a molecular neurosurgery agent, and (ii) the cognate receptor whose
activation results in the selective elimination of a specific subset of neurons in which this
receptor is endogenously expressed. In general, a molecular surgery agent is a selective
and potent ligand, and the target is a specific cell type whose elimination is desired
through the molecular surgery procedure. These target cells have the highest innate
sensitivity to themolecular surgery agent usually due to the highest receptor density being
in their plasma membrane. The interaction between the ligand and its receptor evokes
an overactivity of the receptor. If the receptor is a ligand-activated non-selective cation
channel, the overactivity of receptor leads to excess Ca2+ and Na+ influx into the cell
and finally cell death. One of the best known examples of such an interaction is the effect
of ultrapotent vanilloids on TRPV1-expressing pain-sensing neurons. One intrathecal
resiniferatoxin (RTX) dose allows for the receptor-mediated removal of TRPV1+ neurons
from the peripheral nervous system. The TRPV1 receptor-mediated ion influx induces
necrotic processes, but only in pain-sensing neurons, and usually within an hour. Besides
that, target-specific apoptotic processes are also induced. Thus, as a nano-surgery
scalpel, RTX removes the neurons responsible for generating pain and inflammation
from the peripheral nervous system providing an option in clinical management for the
treatment of morphine-insensitive pain conditions. In the future, the molecular surgery
concept can also be exploited in cancer research for selectively targeting the specific
tumor cell.
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THE CONCEPT OF MOLECULAR SURGERY AND RELATED
TECHNOLOGIES
Our goal with this review is to summarize the basics behind “molecular surgery,” a new concept of
biomedical technology, which have prototyped with the vanilloid receptor type 1 (TRPV1) target.
Currently, resiniferatoxin (RTX) is the number 1 drug candidate to implement the “molecular
neurosurgery” technology at cellular levels. To demonstrate the safety and efficacy of the molecular
Abbreviations: RTX, resiniferatoxin; CAP, capsaicin; TG, trigeminal ganglia; DRG, dorsal root ganglia; FDA, Food and Drug
Administration; NIH, National Institutes of Health; PAM, positive allosteric modulator; CGRP, Calcitonin Gene Related
Peptide; SP, Subtance P; B2B, bench-to-bedside.
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neurosurgery, Dr. Michael J. Iadarola and Dr. Zoltan Olah have
initiated a bench-to-bedside (B2B) project in 2000 that has
recently entered Phase II (Brown D. C. et al., 2015). Headed
by clinicians, the bedside team has already recruited more than
30 cancer pain patients in the clinical trial, which represents a
novel and unique treatment option in clinical management of
morphine-insensitive cancer pain (Brown D. C. et al., 2015).
The current clinical protocol prescribes a single dose of
intrathecal RTX, to treat pain with an agonist of TRPV1 channel.
TRPV1 was molecularly identified in 1997 (Caterina et al.,
1997). TRPV1 belongs to the diverse transient receptor potential
(TRP) family of non-selective cation channels (Benemei et al.,
2015). The human TRP superfamily is composed of 27 members
which are grouped into six subfamilies based on their amino
acid sequence homology: canonical (C), vanilloid (V), melastatin
(M), polycystin (P), mucolipin (ML), and ankyrin (A). They all
share the common feature of six transmembrane domains and
permeability to cations (Montell, 2005).
TRPV1 is dominantly expressed at the source of the
inflammatory pain signals (Patapoutian et al., 2009), thus
agonist-mediated removal of specific TRPV1+ inflammatory
pain-sensing neurons, or “acheurons,” as we call them, can
manage even severe chronic pain situations. The detailed
mechanism, as it has been revealed, is the RTX-induced
cytotoxicity, which exploits the high specificity and affinity of this
exovanilloid to TRPV1. This induces a subsequent flux of Ca2+
and Na+ ions into the acheurons (Olah et al., 2001; Karai et al.,
2004; Pecze et al., 2013).
One of the preferred goals of the clinical trial, started in 2008
in the National Institutes of Health (NIH, Bethesda, Maryland),
is to manage morphine-insensitive, and subsequently unbearable
pain cases that are currently an unmetmedical need. The trial also
will provide evidence on better end-of-life quality and palliative
care of cancer patients and deliver the proof of concept of
molecular neurosurgery: only TRPV1+ acheurons, a verified
subset of sensory neurons, can be removed by RTX-induced
cytotoxicity. The technology is amenable due to the fact that it
is supported by a number of experiments carried out in various
mammals, from rodents to primates (Olah et al., 2001; Karai
et al., 2004; Brown et al., 2005; Tender et al., 2005; Brown D. C.
et al., 2015; Brown, 2016). The methods and kits for the selective
ablation of pain-sensing neurons have been patented (Iadarola
et al., 2012).
Although there are drug leads acting as TRPV1 inhibitors
in different stages of R&D pipelines at a number big pharma
companies (Kaneko and Szallasi, 2014), currently, there is no
vanilloid drug on the market other than capsaicin (CAP). In
contrast to RTX, however, CAP is not an optimal compound
to target TRPV1 and implement the molecular neurosurgery
technology. First of all, ours and others’ experiments validated
that CAP is less potent as an agonist of TRPV1 than RTX
(Szallasi and Blumberg, 1999). In general, one can say that
RTX acts in a low nanomolar range on TRPV1, while CAP
acts in a low micromolar range, but the exact EC50 values
vary between assays (Szallasi and Blumberg, 1999; Olah et al.,
2001). As many pharmaceuticals may lose their specificity at
higher doses, TRPV1-independent cytotoxic effects have been
reported at concentrations above 10 micromolar for RTX and
above several hundred micromolar for CAP, tested on Sf9 insect
cells that do not have the TRPV1 gene (Pecze et al., 2008).
The vanilloid-binding site of TRPV1 is mapped to a protein
region embedded in the lipid membrane, which justifies the use
of the more lipophilic RTX. Thus, currently RTX is the vanilloid
with the highest affinity and efficacy. We have also determined
that CAP, due to its lower affinity and quicker dissociation from
the receptor, is an inappropriate drug for implementation of the
molecular neurosurgery and unable to deliver robust agonist-
induced cytotoxicity within minutes, as noted with RTX, even
in vivo (Olah et al., 2001; Karai et al., 2004; Brown et al., 2005;
Tender et al., 2005).
EXTENDED USE OF THE
AGONIST-INDUCED CYTOTOXIC
MECHANISM FOR PAIN MANAGEMENT
TRPV1 channels are highly expressed on C- and Aδ-type sensory
neurons. The cell bodies of somatic sensory afferent fibers
lie in the dorsal root ganglia (DRG) and trigeminal ganglia
(TG). TRPV1 can be stimulated by (i) endovanilloids, produced
naturally by peripheral tissues in response to injury, (ii) heat
source of moderately high temperature (42–49◦C), and (iii)
extracellular acidosis (pH ∼6.0; Caterina et al., 1997; Tominaga
et al., 1998). Endovanilloids are defined as endogenous ligands
of TRPV1 (van der Stelt and Di Marzo, 2004). Three different
classes of endogenous lipids have been found recently that can
activate TRPV1, and these are unsaturated N-acyldopamines,
lipoxygenase products of arachidonic acid and linolenic acid,
and the endocannabinoid anandamide (van der Stelt and Di
Marzo, 2004). These compounds are produced at the site
of inflammation. Endogenous TRPV1 ligands have different
pharmacological properties (e.g., affinity, potency, metabolic rate,
etc.) compared to naturally occurring exogenous agonists such
as CAP or RTX, and consequently endogenous ligands have
different physiological functions. As an example, endogenous
agonists are involved in the generation of chronic pain,
while exogenous agonists are capable of alleviating chronic
pain (Carnevale and Rohacs, 2016). Potent vanilloids such as
CAP or RTX can be administered in a different manner for
the removal of TRPV1+ neurons. Routes of administration
include (I) topical epicutaneous (application onto the skin),
(II) intraarticular, (III) intrathecal (IV) intraganglionic, and (V)
systemic intraperitoneal.
I. Topical CAP has been used for medicinal puposes for
centuries, mainly to treat toothache. Creams containing
CAP, generally in the range of 0.025–0.1% by weight,
are now available in many countries, and often do not
require a prescription, for the management of neuropathic
and musculoskeletal pain. CAP creams have shown
analgesic benefits in postherapeutic neuralgia, painful
polyneuropathies including diabetic and HIV-related
neuropathy, and postmastectomy/surgical neuropathic
syndromes (Jorge et al., 2010). The CAP 8% patch is
approved by FDA (U.S.Food and Drug Administration)
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for postherapeutic neuralgia. Epidermal nerve fiber density
in skin areas exposed to the high-concentration CAP
patch (8%) was clearly lower 1 week after a single 60-min
application as compared with control biopsies, but at 24
weeks, epidermal nerve fiber density appears similar to the
control (Kennedy et al., 2010). Topical RTX administration
was studied for treatment of ophthalmic pain. In rat cornea,
a single application of RTX dose-dependently eliminated
the CAP-induced eye-wiping response for 3–5 days (Bates
et al., 2010). This analgesic effect was fully reversible (Bates
et al., 2010). The distant surviving neuronal body generates
new C-, and Aδ-afferents, which repairs inflammatory pain
sensation (Donnerer, 2003; Kennedy et al., 2010). Thus,
the analgesic effect of topical vanilloid administration is
reversible.
II. In the sinovial fluid of joints, RTX can inactivate the C-,
and Aδ-nerve pain signaling, but only temporarily.These
nerves recover in a month due to fiber regeneration, guided
by the unaffected axons in the nerve (Neubert et al., 2003;
Kissin E. Y. et al., 2005). This process should be much faster
and more complete after intra-articular than sciatic nerve
RTX administration, due to the shorter part of the ablated
nerve fibers in the first case. These experimented approaches
will provide the possibility for a reversible interruption of
nerve fiber signaling without their complete and irreversible
destruction (Neubert et al., 2003; Kissin E. Y. et al., 2005;
Kissin I. et al., 2005).
III. In contrast to topical administration, other routes of
application generate irreversible changes, because these
treatments eliminate not only the periferal axons, but also
the body of the TRPV1-positive sensory neurons. Complete
removal of the pain sensing neurons are a treatment option
for chronic, uncurable pain conditions, such as cancer pain.
RTX can be equally potent as an ablative agent of C-fiber
and Aδ-afferents in patients with non-terminal stage of
diseases coupled with neuropathic complication, including
chronic phantom pain and type 2 diebetes (Karai et al.,
2004; Brown et al., 2005; Mannes et al., 2005; Neubert
et al., 2005; Tender et al., 2005). We and others have
collected the necessary evidence for the extended use of
the agonist-induced cytotoxic mechanism to carry out
molecular neurosurgery. Due to the extreme specificity of
RTX to TRPV1, the cytotoxicity does not affect other sensory
modalities, such as super-heat, cold, light touch, noxious
mechano-, and proprioceptive sensations. The RTX-assisted
neurosurgery neither impairs bystander motor neurons nor
influences consciousness (Olah et al., 2001; Karai et al., 2004;
Brown et al., 2005; Tender et al., 2005; Patapoutian et al.,
2009). The safety and efficacy of RTX have successfully been
validated even in dogs and monkeys (Olah et al., 2001; Karai
et al., 2004; Brown et al., 2005; Tender et al., 2005; Gunthorpe
and Szallasi, 2008).
IV. In contrast to intrathecal administration, intraganglionic
injection may need an advanced imaging technology R&D
process, in order to fully support robotic anatomical
guidance (i.e., needle placement by computer tomography).
With this technology at hand, we can treat severe focal pain
syndromes right at the source, and remove acheurons from
a sub-domain of DRG or TG branches. One of the well-
defined medical needs in trigeminal neuralgia requires CT-
guided needle placement to inject RTX with an intra-nerve
anatomic precision (Brown J. D. et al., 2015).
V. Prior to transgenic TRPV1 knockout models, systemic
chemo-denervation was employed with potent vanilloids
(Jancso et al., 1967; Szolcsanyi et al., 1990) to study
animal behavior with altered pain sensations. Respiratory
depression represents the limiting factor in rats for acute
and systemic administration of CAP or RTX (Szallasi et al.,
1989). The therapeutic window for RTX is wider than
for CAP. RTX administered at a dosage of 50µg/kg body
weight effectively removed all pain-sensing neurons in
young adult mice (Pecze et al., 2009). Mice survived the
procedure and lived to an old age in the animal facility. They
remained fertile, however they were not able to adapt to heat
stress (Pecze et al., 2009). If subjected to elevated ambient
temperature (38◦C), RTX-treated rats showed a steady rise in
body temperature, ultimately leading to collapse, in contrast
to control animals, which did not show these behaviors
(Szallasi and Blumberg, 1989).
In conclusion, RTX usually provides a better pharmacological
profile than CAP. CAP is effective in micromolar concentrations
and ranked approximately three factors of magnitude less potent
as a vanilloid agonist than RTX. Although RTX is more potent,
paradoxically it evokes less pain feeling than CAP, because the
initial activation of the pain pathway via TRPV1 is immediately
cut by the ionic influx-induced fragmentations of pain-sensing C-
and Aδ-fibers. Even an intrathecally administered 1µg/kg dose
of RTX can rapidly eradicate the inflammatory pain signaling
by a robust TRPV1-amplified cytotoxicity without significant
side effect, tested in patient dogs suffering either cancer or
osteoporosis pain (Brown et al., 2005). At the site of application
the action potential conductivity of the acheuron’s membranes
is blocked in seconds, either when RTX is given proximally
(i.e., intrathecal, intraganglionic) or distally (i.e., transdermal)
to the neuronal body. Thus, only a small dosage of noxious
stimuli can reach the central nervous system (Caudle et al.,
2003; Neubert et al., 2003; Karai et al., 2004). In the veterinary
practice, RTX-treatments of severe cancer and osteoporotic
patient dogs have demonstrated initial, short-lived physiological
changes, but then the blood pressure and cardiac parameters
went back to the normal range. The benefit of longterm and
permanent elimination of unbearable inflammatory pain justifies
the effective ablation of acheurons (Karai et al., 2004; Tender
et al., 2005).
EMPIRICAL USAGE OF MOLECULAR
SURGERY
Nowadays, rational and mechanism-based applications of
technologies based on specific molecular surgery agents can
replace previous empiric practices. The surface of the human
body, externally, while the gastrointestinal system, internally,
are continuously exposed to pungent compounds such as
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CAP, gingerol, piperine, allyl-isothiocyanate (i.e., chili pepper,
ginger, black pepper, and mustard, respectively), and other
phytochemicals from spices for hundreds or thousands of
years (Iwasaki et al., 2008; Masamoto et al., 2009). Likewise,
either by chance or conscious use, RTX had been applied in
human since the ancient times. Tribal witchdoctors in Africa
often administered the latex from different Euphorbia species
to the wound after removal of a tooth to diminished pain
and inflammation. Empirically, a number of pungent vanilloids
supplement our daily meals. Various Hungarian dishes are made
exclusively with hot peppers, so the human body is frequently
exposed to vanilloids. In Asia as well, different pungent bioactive
ingredients are used in their daily diet and target either the
TRPV1 or TRPA1 channels. Thus, many of the agents mentioned
in this review are administered to humans, either by frequent
consumption or empiric application, first as folk medicine, then
in medical practice (Sterner and Szallasi, 1999; Szallasi and
Blumberg, 1999). Epidemiologic evaluations and natural uses
have demonstrated that these bioactive phytochemicals can save
medical expenses and prolong lifespan. A large cohort study
revealed that consumption of spicy food is inversely correlated
with the mortality caused by cancer, ischemic heart diseases and
respiratory diseases (Lv et al., 2015).
THE ROLE OF ADVANCED IMAGING
TOOLS
For the exploration of the function of the TRPV1 channel,
confocal fluorescence microscopy was vastly instrumental.
Firstly, confocal microscopy was used for the imaging of
dynamics in intracellular free Ca2+ concentrations ([Ca2+]i)
(Figure 1). Moreover, by tagging of TRPV1 channel with
fluorescent proteins, the mechanism of cell death became visually
trackable in real-time (Figure 2 and Supplementary Video; Olah
et al., 2001). Both N- and C-terminally tagged TRPV1 proteins
results in fully functional TRPV1 channels. Cells ectopically
expressing the TRPV1 receptor show necrotic bleb formation
upon CAP stimulation (Pecze et al., 2013). Bleb formation is
dependent on both Ca2+ and Na+ influx (Pecze et al., 2016b).
Bleb formation can be so intensive that the cell blows up,
until finally the loss of the plasma membrane integrity leads
to necrotic cell death (Pecze et al., 2016b). Besides this, cell
organelles such as the mitochondria and endoplasmic reticulum
also show fragmentization within 1 h (Olah et al., 2001). High
resolution confocal images has helped in the figuring out of the
molecular neurosurgery mechanism and in distinguishing the
difference between the efficacy of CAP and RTX (Olah et al.,
2001). Cells ectopically expressing fluorescently tagged TRPV1
channels were voltage-clamped and 10µM CAP induced large
inward currents similar to that of 125 pM RTX. Capsazepine, a
competitive TRPV1 antagonist, attenuated the vanilloid-induced
currents (Olah et al., 2001; Liu et al., 2003; Marshall et al.,
2003).
Fusion of TRPV1 with rationally chosen fluorescent protein
allows for co-localization studies which exploit the fluorescence
resonance energy transfer (FRET) phenomenon (Hellwig
et al., 2005; Zagotta et al., 2016). The optical sectioning
capabilities of confocal fluorescence microscopes followed
by 3D reconstruction revealed the innervation pattern of the
epithelium of guinea-pig trachea by TRPV1 immunoreactive
axons (Watanabe et al., 2005). Confocal images showed the loss
of TRPV1-immunoreactive DRG neurons and afferent terminals
in the spinal cord after RTX treatment (Chen and Pan, 2006).
Ectopically expressed fusion proteins allowed for the
determination of the sub-cellular distribution of TRPV1
receptors. It became clear that in addition to the plasma
membrane (PM), where previously, TRPV1 was expected to
mechanistically localize (TRPV1PM), it was also found and noted
to operate in the endoplasmic reticulum (TRPV1ER), as well
(Olah et al., 2001; Karai et al., 2004). The endoplasmic reticulum
(ER) is the major intracellular storage of Ca2+ ions and like
FIGURE 1 | Ca2+ imaging. (A) NIH-3T3 cells ectopically expressing TRPV1 were loaded with the cytosolic Ca2+ indicator Fluo-4-AM. (B) Minute scales imaging of
[Ca2+]i reveals two populations in NIH-3T3
TRPV1 cell line. A set of cells responds to 1µM CAP with non-declining increase of [Ca2+]i and dies very soon while the
other population survives the initial necrotic-phase in which the [Ca2+]i transitions back to closed to its resting levels. This later option rarely occurs with RTX, as RTX
is several thousandfold more potent than CAP in several assays (Szallasi and Blumberg, 1999). The original experiment was published in 2004 (Karai et al., 2004).
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FIGURE 2 | Time-lapse analysis of vanilloid evoked structural changes in MCF7 breast cancer cell line. MCF7 cells were transiently transfected with TRPV1-GFP
construct. These show green fluorescence. Cells were treated with 50µM CAP. TRPV1-GFP expressing cells, and only these cells, blow blebs during a 10-min period
(red arrowheads). MCF7 cells also endogenously express low levels of TRPV1 channels. This level is not enough to induce bleb formation, but some MCF7 cells
produce invadopodium, an ameboid structure promoting cancer cell invasion, in response to CAP treatment (yellow arrowheads). The original experiment was
published in 2016 (Pecze et al., 2016b).
TRPV1PM, the TRPV1ER receptor is also gated by vanilloids and
contributes to the agonist-induced cytotoxicity. The potency
of less lipophilic CAP on TRPV1ER, is likely hampered by its
slow membrane penetration and distribution to deeper cellular
compartments (Lazar et al., 2006).
MECHANISM OF ACTION
In physiological conditions, TRPV1 is activated by the
endogeneous ligand produced at the site of inflammation
or tissue injury. TRPV1 is a non-selective cation channel
with a higher permeability for divalent cations, such as Ca2+
(permeability ratio PCa/PNa is around ∼10; Gees et al., 2010).
However, both Ca2+ and Na+ influxes through the TRPV1
channel play a role in the transmission of nociceptive signals
from the periphery toward the central nervous system. Besides
this, activation of TRPV1 causes cell depolarization. Sensory
neurons as excitable cells express voltage-operated ion channels.
Activation of TRPV1 channels triggers the gating of those
channels. The firing pattern of neuronal cells is modulated
by conductance changes via TRP channel activation or
inhibition (Gees et al., 2010). It is worth noting that TRPV1
produces an analog Ca2+ signal i.e., the amount of Ca2+ ions
passing through the channel is proportional to the stimulus
intensity. The activated inositol phospholipid pathway acts as
an amplifier and frequency-based modulator on Ca2+ signals
produced by TRPV1. The frequency of the intracellular Ca2+
oscillations are related to the strength of TRPV1 stimulation
(Pecze et al., 2016a). Since exogenous TRPV1 ligands (CAP
and RTX) have different pharmacological properties such
as higher affinity and potency compared to endogenous
agonists, they consequently induce an over-activity of the
TRPV1 receptor. Thus, RTX and CAP induce a prolonged
increase in [Ca2+]i, but only in sensory neurons expressing
TRPV1 while not in other cells (Olah et al., 2001; Karai et al.,
2004).
DESENSITIZATION VS. DELETION OF A
CELL/NEURON
Desensitization is the phenomenon in which a receptor’s
responsiveness decreases after continued or repeated stimulation
with an agonist. Prolonged or repeated applications of
CAP causes persistent desensitization of TRPV1 in an
electrophysiology-based experiment (Touska et al., 2011).
Although this effect can also contribute to pain insensitivity
after vanilloid treatment to some extent, our experiments show
that sensory neurons or axons were absent in the treated region.
Thus, in contrast to desensitization, an alternative mechanism
of potent vanilloids has been proposed; complete removal of
TRPV1-specific nociceptive neurons is the cause of the long-
lasting/permanent inflammatory pain-free state (Olah et al.,
2001; Caudle et al., 2003; Karai et al., 2004) and these findings
were later confirmed by others (Chen and Pan, 2006; Kennedy
et al., 2010; Kun et al., 2012).
However, controversy regarding nerve fiber degeneration vs.
long-lasting desensitization without neuronal degeneration still
exists in terms of the explanation for the mechanism of potent
vanilloid agonism. Prior to transgenic TRPV1 knockout models,
chemo-denervation was employed with potent vanilloids (Jancso
et al., 1967; Szolcsanyi et al., 1990) to study animal behavior
without pain sensation. Although the inflammatory pain-free
state that either CAP or RTX treatment produced was unusually
long lasting (Szallasi et al., 1989; Szallasi and Blumberg, 1992),
more than minutes or hours, the early explanations of the
analgesic actions of vanilloids suggested a desensitization of
nerve terminals (Szolcsanyi et al., 1975). Thus, the literature still
uses long-lasting desensitization as an explanation.
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NECROTIC VS. APOPTOTIC PROCESSES
It was determined in a number of experiments that RTX
(i.e., 1µg/kg) produces analgesia by robust Ca2+-mediated
cytotoxicity, if applied (i) intradermally, lasting for several days to
a month, or (ii) intrathecally and intraganglionically, permanent
for a lifetime, removing the entire TRPV1+ neuron (Szabo et al.,
1999; Karai et al., 2004).
The cellular and molecular mechanisms underlying the
vanilloid-induced neural loss are still unresolved. Evidence for
CAP-induced neuronal cell death by apoptosis with caspase
activation has been reported (Shin et al., 2003; Jin et al., 2005),
while some studies state that it is an apoptosis-like, but caspase-
independent process (Movsesyan et al., 2004; Davies et al.,
2010). Still other studies doubt the process to be apoptotic
at all in nature (Olah et al., 2001; Caudle et al., 2003). It is
very likely that both apoptosis and necrosis might play a role
in TRPV1-mediated toxicity, depending on the strength of the
activation and moreover on the experimental protocol. The Ca2+
ionophore ionomycin acts by creating Ca2+-permeable pores in
cell membranes. Analagous to TRPV1-related cytotoxicity, it can
induce either apoptosis or necrosis in cultured cortical neurons
(Gwag et al., 1999).
The MCF7 breast cancer cell line, although it expresses
endogeneously low levels of TRPV1 receptors, cannot be
subjected to necrotic-like procecesses by administration of CAP
or RTX, but shows the typical structural changes when TRPV1
is ectopically overexpressed (Figure 2). Interestingly, in MCF7
cells, the mere overexpression of GFP-tagged TRPV1 channels
decreased cell viability (Pecze et al., 2016b). We observed that
mainly apoptotic processes were activated, but mitotic arrest in
MCF7GFP-TRPV1 cells was also detected. The absence of mitosis
in the surviving MCF7GFP-TRPV1 cells subsequently did not allow
for the establishment of stable MCF7GFP-TRPV1 clones, although
we had been successful in establishing cell clones permanently
expressing ectopic TRPV1 proteins using non-tumor-derived cell
lines such as HaCaT, a spontaneously immortalized keratinocyte
cell line from adult human skin (Pecze et al., 2008), or NIH-3T3
cells, a spontaneously immortalized mouse embryo fibroblast
cell line (Olah et al., 2007). Moreover, prolonged treatment
of non-transfected MCF7 cells with CAP induces apoptotic
processes due to increased oxidative stress (Kosar et al., 2016).
The supposedmechanisms of necrotic and apoptoic processes are
summarized in Figure 3.
SAFETY AND EFFICACY OF MOLECULAR
SURGERY AGENTS IN HUMANS
Resistance to vanilloids provides additional safety and efficacy
to the molecular surgery technology. We and others have noted
that TRPV1 and its mRNA are detected in a broader spectra of
cells rather than only from DRG or TG origins. Paradoxically,
the occurrence of TRPV1 does not necessarily mean that the cell
can automatically be deleted by the vanilloid-mediated molecular
surgery. Vanilloid binding cannot be mechanistically linked
either to channel opening or to permanent elevation in [Ca2+]i.
FIGURE 3 | Necrotic and apoptotic processes after TRPV1 stimulation. (A) In
the unstimulated state, the resting [Ca2+]i is the result of the low rate of influx
and efflux across the plasma, ER- and mitochondria membranes. Red and
blue arrows indicates the energy-requiring and energy-independent fluxes,
respectively. After stimulation, two types of Ca2+ response can be observable
leading to necrotic (B) and potentially apoptotic processes (C). (B) During the
necrotic processes TRPV1 activation results in a sustained increase in [Ca2+]i.
After that, Ca2+ ions are accumulated in the mitochondria (Pecze et al.,
2016b) but released from the endoplasmatic reticulum. These processes lead
to the fragmentation of these organelles (Olah et al., 2001). Blebs appears at
the plasmamembrane due to the cell volume increase. (C) During the
apoptotic processes TRPV1 activation does not result in a sustained increase
in [Ca2+]i, but rather to a transient Ca
2+ signal mainly due to the depletion of
the ER Ca2+ stores. In this situation, Ca2+ extruding systems is still able to
create an equilibrium between the Ca2+ influx and Ca2+ efflux reverting
[Ca2+]i close to its basal levels before stimulation. However, this new
equilibrium requires elevated energy consumption. Mitochondria therefore
produce more energy, but during their normal operation they also produce
reactive oxygene species (ROS; Michael Murphy, 2009). ROS production was
significantly increased in cultured DRG neurons after bath application of CAP
(1µM) or RTX (200 nM) compared with the untreated neurons (Ma et al.,
2009). This can induce oxidative stress and apoptosis Fleury et al., 2002.
This issue has been addressed in studies of human keratinocytes
(Pecze et al., 2008; Kun et al., 2012).
One potential explanation for vanilloid resistance is that
TRPV1 subunits need to form a homotetramer channel,
a quaternary structure required for maximal vanilloid
sensitivity and channel activity (Kedei et al., 2001; Garcia-
Sanz et al., 2004; Moiseenkova-Bell et al., 2008). Any
obstacles that hamper quaternary structure formation of
the pore from the subunits may reduce the cell’s sensitivity to
vanilloids. Mounting evidence shows that TRPV1 is capable
of heteromerization with other TRP channel homologs upon
co-expression (Fischer et al., 2014). Major determinants of
TRPV1 oligomerization have recently been localized to the
C-terminal 684Glu-721Arg, the so-called association domain
(Garcia-Sanz et al., 2004). Recombinant association domains
form stable multimers, however, association domain-deleted
TRPV1 is monomeric and blocks self-assembly of wild-
type subunits in functional homotetramers. Evolutionarily
conserved, homologous, but not identical, association domains,
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however, may allow for the combinatorial assembly of different
TRP channels that are gated by distinct ligands other than
vanilloids.
Besides this, our experiments indicate that TRPV1 channel
density on the plasma membrane is an important factor for the
cell’s sensitivity to vanilloids (Pecze et al., 2016b). Cells expressing
lower density of the TRPV1 channel are evidently more resistant
to TRPV1-mediated cytotoxicity. Unfortuntely, although tumor
cells express higher levels of TRPV1 than normal epithelial
cells, they still do not have enough receptors to perform tumor-
targeted TRPV1-mediated necrotic-type eradication (Pecze et al.,
2016b). Nevertheless, several experiments (Diaz-Laviada and
Rodriguez-Henche, 2014) as well as a case report (Jankovic
et al., 2010) suggest that vanilloids have anti-cancer activity. The
origin of the anticancer effects of vanilloids is not completely
solved and it needs further examination. Whether it is TRPV1-
mediated or a TRPV1-independent effect is still in question
(Diaz-Laviada and Rodriguez-Henche, 2014). To make things
more complicated, pain sensing neurons innervate the tumor
mass and communicate with the tumors (Li et al., 2013).
Systemic removal of TRPV1+ neurons in mice increased
the number of metastasis of breast cancers (Erin et al.,
2004).
PROOF OF THE EFFICACY OF
MOLECULAR NEUROSURGERY FOR THE
TREATMENT OF TYPE II DIABETES AND
URINARY DISFUNCTIONS
The proof of the applicability of molecular surgery reveals a
second use of RTX in type II diabetes as an anti-neuropathic
treatment agent (Gram et al., 2005; Moesgaard et al., 2005).
The system that regulates insulin secretion from beta-cells
in the islet of Langerhans has a vanilloid-sensitive inhibitory
component. Calcitonin Gene Related Peptid (CGRP)-expressing
TRPV1+ primary sensory fibers innervate the islets. The CGRP-
containing primary sensory neurons are targets of the RTX-
mediated molecular neurosurgery. Elimination of vanilloid-
sensitive primary afferents by vanilloids before the development
of hyperglycemia prevents the increase of plasma glucose levels
and coincides with enhanced insulin secretion and a loss of
CGRP-expressing islet-innervating fibers. These data indicate
that CGRP-containing fibers in the islets are sensitive to
molecular neurosurgery, and that elimination of these fibers
contributes to the prevention of the deterioration of glucose
homeostasis through increased insulin secretion in genetically
obese rats (Gram et al., 2005, 2007; Moesgaard et al., 2005).
Vanilloid-sensitive C- and Aδ-afferents are present in the
human bladder’s urothelium and are involved in the micturition
reflex. Although, intravesically administered RTXmost likely acts
analogous to CAP, its better pharmacodynamic profile allows
for an increase in bladder volume and a higher threshold for
the micturition reflex (Payne et al., 2005; Raisinghani et al.,
2005). This improvement coincides with a disappearance of
CGRP and Substance P (SP) immunoreactive fibers, selective
biomarkers of afferents of TRPV1+ neurons. Thus, the loss of
CGRP and SP peptide immunoreactivity, consistent either with
agonist-mediated depletion of neurotransmitters, or deletion
of these fibers by vanilloid-mediated Ca2+-cytotoxicity via
molecular neurosurgery.
Overactive bladder syndrome, a common type of micturition
disorder, can lead to the loss of bladder control, which is
then known as urge incontinence. First CAP (Szallasi et al.,
1993; De Ridder et al., 1997), then RTX (Lazzeri et al., 1997),
were tried as experimental drugs to inactivate incontinency
in the clinical settings (Figure 4). It has been long known
that these reflexes in the bladder are mediated by C- and
Aδ-fiber afferents of nociceptive neurons located in the sacral
DRGs. The Afferon Inc., in the late 90’s, patented a method of
treating neurogenic urinary dysfunction with RTX (Cruz and
Agersborg, 2014), and has enrolled patients affected with urge
incontinence due to various neurological diseases. The Afferon
was admitted into phase II clinical trials. Currently, Eli Lilly
and Company has exclusive worldwide license rights for the
commercial use of RTX for the treatment of bladder disease
or function. Unfortunately, in contrast to these practices (Guo
et al., 2013; Foster and Lake, 2014), RTX is still not a registered
drug.
Nevertheless, the effectiveness of intravesical RTX treatment
strongly varies from study to study. The reasons for these
inconsistencies in the clinical outcome might be manifold: too
dilute samples of vanilloids were used, different origins of the
FIGURE 4 | Topical intravesical medication of RTX via transurethral instillation
promises several advantages over oral systemic CAP therapy. Intravesically
administered RTX penetrates the vesical mucosa and submucosa by diffusion
and binds to TRPV1+ nerve endings. The suggested “balloon dilator” method
benefits from the increased surface of urothelium due to the thinning of the
bladder mucosa.
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latent disease resulting in urinary disfunction, or the simple lack
of a significant effect of RTX in a specific type of urinary problem.
We would like to pay attention to the fact that strong adsorption
of RTX and CAP molecules into the tubes of the application
devices might also occur. These technical problems can cause a
huge variance in the clinical outcomes. Animal experiments will
be required to obtain the appropriate material for these tubes. By
using a water-soluble formulation of vanilloids (Appendino et al.,
2010) the adsorption of vanilloid molecules onto the tubes might
also be avoidable. The loss of the TRPV1+ nerve endings in the
urothelium can serve as a marker for the successful intravesical
instillation.
OTHER AGONIST-ACTIVATED
CA2+-CHANNELS AS TARGETS OF NOVEL
MOLECULAR SURGERY AGENTS
The molecular mechanism of TRPV1-mediated cytotoxicity
shows conspicuous similarity to glutamate-receptor mediated
excitotoxicity, i.e., robust Na+ and Ca2+ influx, cell swelling,
mitochondrial Ca2+ loading, and production of reactive oxygen
species (Dong et al., 2016). Ionotropic glutamate receptors, as
glutamate is the main excitatory neurotransmitters in the central
nervous system, play important role in production of excitatory
postsynaptic potentials, neuronal migration, synapse formation,
learning, and memory (Choi and Rothman, 1990; Dugan et al.,
1995). Kainic acid, an agonist for kainate-class ionotropic
glutamate receptors, is commonly injected into laboratory animal
models to study the effects of experimental ablation. However,
attempts to limit cell loss to specific hippocampal neurons
have been met with mixed successes and failures (Jarrard,
2002).
The concept ofmoleculary surgery would be an ideal approach
for cancer treatment. Tumors express a different composition
of TRP channels than normal cells (Park et al., 2016). Finding
a specific TRP target overexpressed only in the tumor cells and
finding a potent agonist would provide an ideal pair for the
tumor-specific eradication. Recently, it was found that kidney
cancer cells can be efficiently and specifically targeted by (-)-
Englerin A, a potent and selective activator of TRPC4 and TRPC5
channels (Akbulut et al., 2015). The renal cancer cell line A498,
which is most sensitive for (-)-Englerin A, has a highest degree of
expression of TRPC4 among the NCI60 cell lines (Akbulut et al.,
2015). New derivatives of (-)-Englerin A have been synthetized
in order to find effective drugs for the treatment of renal cell
carcinoma. A patent application has been filed for this treatment
(Echavarren et al., 2011). These new derivatives open a new way
of the final goal of finding effective drugs for the treatment of
renal cell carcinoma.
CONCLUSIONS AND PERSPECTIVES
Evidence-based and clinically-tried B2B-approaches, such as
molecular neurosurgery prototyped with RTX and TRPV1
channel, can be extended for other applications. Here we
put an emphasis to the analgesic use of the agonist-induced
selective cytotoxic mechanism, however by analogy, a number
of robust, biological cell deletion mechanisms may be used
in the near future. For example, treatment of metastatic
cancers might be amenable by using cancer-specific TRP
targets.
Currently, RTX is the most powerful molecular surgery agent
in Phase II clinical trials to manage cancer pain in humans.
RTX has also been evaluated in severe inflammatory pain states
and various neuropathies, as it only removes acheurons and
preserves any other bystander cells, fibers, and nerve endings,
with little or no side-effects. RTX works in conjunction with
TRPV1, with a lack of any effect to cells which do not express
TRPV1.
Combination treatment, however, may extend the utility
of CAP or other weaker agonists enhancing the cytotoxic
effect of vanilloids. A family of positive allosteric modulators
(PAM) of TRPV1 only activates Na+ and Ca2+ entry via the
vanilloid receptor channel if a vanilloid (CAP, RTX, piperine,
etc.) is already bound to the receptor (Roh et al., 2008).
These compounds extend the molecular tools of molecular
surgery. PAM further increases by 2–3-fold the maximal effect
of vanilloids on the induction of Na+/Ca2+-uptake, producing
little or no action when used alone (Roh et al., 2008; Kaszas
et al., 2011; Lebovitz et al., 2012). Thus, weaker exovanilloids
such as CAP and piperine, present in hot peppers and black
peppers, or even weaker endovanilloids can serve as agents to
fight against inflammation, pain, and neuropathies. Morevover,
RTX, together with a PAM molecule, MRS1477, can provide
innovative solutions to number of currently unmet medical
needs. The exact mechanism of positive allosteric modulation
and the domain specificity of the binding site is not enterely
known. Therefore, a more detailed quantitative structure-activity
relationship and the determination of the TRPV1-mediated
cytotoxic capacity of PAMs must be examined by further
studies.
AUTHOR CONTRIBUTIONS
LP, ZO wrote the review BV critically revised the work and
approved its version to be submitted.
ACKNOWLEDGMENTS
The authors wish to thank Miss Andrea Guljas, University of
Toronto, who assisted in the proof-reading of themanuscript. ZO
was funded by the GINOP 2.3.2 program, started in 2017.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: http://journal.frontiersin.org/article/10.3389/fphys.
2017.00378/full#supplementary-material
Frontiers in Physiology | www.frontiersin.org 8 June 2017 | Volume 8 | Article 378
Pecze et al. Molecular Surgery Concept from Bench to Bedside
REFERENCES
Akbulut, Y., Gaunt, H. J., Muraki, K., Ludlow, M. J., Amer, M. S., Bruns, A., et al.
(2015). (−)-Englerin A is a potent and selective activator of TRPC4 and TRPC5
calcium channels. Angew. Chem. 127, 3858–3862. doi: 10.1002/ange.2014
11511
Appendino, G., Ech-Chahad, A., Minassi, A., De Petrocellis, L., and Marzo,
V. D. (2010). Structure–activity relationships of the ultrapotent vanilloid
resiniferatoxin (RTX): the side chain benzylic methylene. Bioorg. Med. Chem.
Lett. 20, 97–99. doi: 10.1016/j.bmcl.2009.11.035
Bates, B. D., Mitchell, K., Keller, J. M., Chan, C. C., Swaim, W. D., Yaskovich, R.,
et al. (2010). Prolonged analgesic response of cornea to topical resiniferatoxin,
a potent TRPV1 agonist. Pain 149, 522–528. doi: 10.1016/j.pain.2010.03.024
Benemei, S., Patacchini, R., Trevisani, M., and Geppetti, P. (2015). TRP
channels. Curr. Opin. Pharmacol. 22, 18–23. doi: 10.1016/j.coph.2015.
02.006
Brown, D. C. (2016). Resiniferatoxin: the evolution of the “molecular scalpel”: for
chronic pain relief. Pharmaceuticals 9:47. doi: 10.3390/ph9030047
Brown, D. C., Agnello, K., and Iadarola, M. J. (2015). Intrathecal resiniferatoxin
in a dog model: efficacy in bone cancer pain. Pain 156, 1018–1024.
doi: 10.1097/j.pain.0000000000000115
Brown, D. C., Iadarola, M. J., Perkowski, S. Z., Erin, H., Shofer, F., Laszlo,
K. J., et al. (2005). Physiologic and antinociceptive effects of intrathecal
resiniferatoxin in a canine bone cancer model. Anesthesiology 103, 1052–1059.
doi: 10.1097/00000542-200511000-00020
Brown, J. D., Saeed, M., Do, L., Braz, J., Basbaum, A. I., Iadarola, M. J.,
et al. (2015). CT-guided injection of a TRPV1 agonist around dorsal root
ganglia decreases pain transmission in swine. Sci. Transl. Med. 7:305ra145.
doi: 10.1126/scitranslmed.aac6589
Carnevale, V., and Rohacs, T. (2016). TRPV1: a Target for Rational Drug Design.
Pharmaceuticals 9:52. doi: 10.3390/ph9030052
Caterina, M. J., Schumacher, M. A., Tominaga, M., Rosen, T. A., Levine, J. D., and
Julius, D. (1997). The capsaicin receptor: a heat-activated ion channel in the
pain pathway. Nature 389, 816–824. doi: 10.1038/39807
Caudle, R. M., Karai, L., Mena, N., Cooper, B. Y., Mannes, A. J., Perez, F.
M., et al. (2003). Resiniferatoxin-induced loss of plasma membrane
in vanilloid receptor expressing cells. Neurotoxicology 24, 895–908.
doi: 10.1016/S0161-813X(03)00146-3
Chen, R.-S., and Pan, L.-H. (2006). Loss of TRPV1-expressing sensory neurons
reduces spinalµ opioid receptors but paradoxically potentiates opioid
analgesia. J. Neurophysiol. 95, 3086–3096. doi: 10.1152/jn.01343.2005
Choi, D. W., and Rothman, S. M. (1990). The role of glutamate neurotoxicity
in hypoxic-ischemic neuronal death. Annu. Rev. Neurosci. 13, 171–182.
doi: 10.1146/annurev.ne.13.030190.001131
Cruz, F., and Agersborg, H. P. K. (2014). Urinary Incontinence Therapy, Google
Patents, 2003.
Davies, J. W., Hainsworth, A. H., Guerin, C. J., and Lambert, D. G.
(2010). Pharmacology of capsaicin-, anandamide-, and N-arachidonoyl-
dopamine-evoked cell death in a homogeneous transient receptor potential
vanilloid subtype 1 receptor population. Br. J. Anaesth. 104, 596–602.
doi: 10.1093/bja/aeq067
De Ridder, D., Chandiramani, V., Dasgupta, P., Van Poppel, H., Baert, L., and
Fowler, C. J. (1997). Intravesical capsaicin as a treatment for refractory detrusor
hyperreflexia: a dual center study with long-term followup. J. Urol. 158,
2087–2092. doi: 10.1016/s0022-5347(01)68162-x
Diaz-Laviada, I., and Rodriguez-Henche, N. (2014). The potential antitumor
effects of capsaicin. Prog. Drug Res. 68, 181–208. doi: 10.1007/978-3-0348-
0828-6_8
Dong, M., Li, H., Hu, D., Zhao, W., Zhu, X., and Ai, H. (2016). Molecular
dynamics study on the inhibition mechanisms of drugs CQ1−3 for alzheimer
amyloid-β40 aggregation induced by Cu
2+. ACS Chem. Neurosci. 7, 599–614.
doi: 10.1021/acschemneuro.5b00343
Donnerer, J. (2003). Regeneration of primary sensory neurons. Pharmacology 67
169–181. doi: 10.1159/000068405
Dugan, L. L., Sensi, S. L., Canzoniero, L. M., Handran, S. D., Rothman, S. M.,
Lin, T. S., et al. (1995). Mitochondrial production of reactive oxygen species
in cortical neurons following exposure to N-methyl-D-aspartate. J. Neurosci.
15 6377–6388.
Echavarren, P. A. M., Molawi, K., and Delpont, N. P. R. (2011). A Process for
the Preparation of (−)-Englerin a, and Analogues and Intermediates Thereof,
Google Patents.
Erin, N., Boyer, P. J., Bonneau, R. H., Clawson, G. A., and Welch, D. R. (2004).
Capsaicin-mediated denervation of sensory neurons promotes mammary
tumor metastasis to lung and heart. Anticancer Res. 24, 1003–1009. Available
online at: http://ar.iiarjournals.org/content/24/2B/1003.long
Fischer, M. J., Balasuriya, D., Jeggle, P., Goetze, T. A., McNaughton, P. A., Reeh,
P. W., et al. (2014). Direct evidence for functional TRPV1/TRPA1 heteromers.
Pflugers Arch. 466, 2229–2241. doi: 10.1007/s00424-014-1497-z
Fleury, C., Mignotte, B., and Vayssière, J.-L. (2002). Mitochondrial
reactive oxygen species in cell death signaling. Biochimie 84, 131–141.
doi: 10.1016/S0300-9084(02)01369-X
Foster, H. E. Jr., and Lake, A. G. (2014). Use of vanilloids in urologic disorders.
Prog. Drug Res. 68, 307–317. doi: 10.1007/978-3-0348-0828-6_13
Garcia-Sanz, N., Fernandez-Carvajal, A., Morenilla-Palao, C., Planells-Cases, R.,
Fajardo-Sanchez, E., Fernandez-Ballester, G., et al. (2004). Identification of a
tetramerization domain in the C terminus of the vanilloid receptor. J. Neurosci.
24, 5307–5314. doi: 10.1523/jneurosci.0202-04.2004
Gees, M., Colsoul, B., and Nilius, B. (2010). The role of transient receptor potential
cation channels in Ca2+ signaling. Cold Spring Harb. Perspect. Biol. 2:a003962.
doi: 10.1101/cshperspect.a003962
Gram, D. X., Ahren, B., Nagy, I., Olsen, U. B., Brand, C. L., Sundler, F.,
et al. (2007). Capsaicin-sensitive sensory fibers in the islets of Langerhans
contribute to defective insulin secretion in Zucker diabetic rat, an animal model
for some aspects of human type 2 diabetes. Eur. J. Neurosci. 25, 213–223.
doi: 10.1111/j.1460-9568.2006.05261.x
Gram, D. X., Hansen, A. J., Deacon, C. F., Brand, C. L., Ribel, U., Wilken, M.,
et al. (2005). Sensory nerve desensitization by resiniferatoxin improves glucose
tolerance and increases insulin secretion in Zucker Diabetic Fatty rats and
is associated with reduced plasma activity of dipeptidyl peptidase IV. Eur. J.
Pharmacol. 509, 211–217. doi: 10.1016/j.ejphar.2004.12.039
Gunthorpe, M. J., and Szallasi, A. (2008). Peripheral TRPV1 receptors as targets
for drug development: new molecules and mechanisms. Curr. Pharm. Des. 14,
32–41. doi: 10.2174/138161208783330754
Guo, C., Yang, B., Gu, W., Peng, B., Xia, S., Yang, F., et al. (2013). Intravesical
resiniferatoxin for the treatment of storage lower urinary tract symptoms in
patients with either interstitial cystitis or detrusor overactivity: a meta-analysis.
PLoS ONE 8:e82591. doi: 10.1371/journal.pone.0082591
Gwag, B. J., Canzoniero, M. L., Sensi, S. L., DeMaro, J. A., Koh, J. Y.,
Goldberg, M. P., et al. (1999). Calcium ionophores can induce either
apoptosis or necrosis in cultured cortical neurons.Neuroscience 90, 1339–1348.
doi: 10.1016/s0306-4522(98)00508-9
Hellwig, N., Albrecht, N., Harteneck, C., Schultz, G., and Schaefer, M. (2005).
Homo- and heteromeric assembly of TRPV channel subunits. J. Cell Sci. 118,
917–928. doi: 10.1242/jcs.01675
Iadarola, M. J., Olah, Z., and Karai, L. (2012). Selective Ablation of Pain-Sensing
Neurons by Administration of a Vanilloid Receptor Agonist, US patent 8,338,457.
Iwasaki, Y., Tanabe, M., Kobata, K., and Watanabe, T. (2008). TRPA1 agonists–
allyl isothiocyanate and cinnamaldehyde–induce adrenaline secretion. Biosci.
Biotechnol. Biochem. 72, 2608–2614. doi: 10.1271/bbb.80289
Jancso, N., Jancso-Gabor, A., and Szolcsanyi, J. (1967). Direct evidence
for neurogenic inflammation and its prevention by denervation and by
pretreatment with capsaicin. Br. J. Pharmacol. Chemother. 31, 138–151.
doi: 10.1111/j.1476-5381.1967.tb01984.x
Jankovic, B., Loblaw, D. A., and Nam, R. (2010). Capsaicin may slow PSA
doubling time: case report and literature review. Can. Urol. Assoc. J. 4, E9–E11.
doi: 10.5489/cuaj.784
Jarrard, L. E. (2002). Use of excitotoxins to lesion the hippocampus: update.
Hippocampus 12, 405–414. doi: 10.1002/hipo.10054
Jin, H. W., Ichikawa, H., Fujita, M., Yamaai, T., Mukae, K., Nomura,
K., et al. (2005). Involvement of caspase cascade in capsaicin-induced
apoptosis of dorsal root ganglion neurons. Brain Res. 1056, 139–144.
doi: 10.1016/j.brainres.2005.07.025
Jorge, L. L., Feres, C. C., and Teles, V. E. (2010). Topical preparations for pain relief:
efficacy and patient adherence. J. Pain Res. 4, 11–24. doi: 10.2147/JPR.S9492
Kaneko, Y., and Szallasi, A. (2014). Transient receptor potential (TRP) channels: a
clinical perspective. Br. J. Pharmacol. 171, 2474–2507. doi: 10.1111/bph.12414
Frontiers in Physiology | www.frontiersin.org 9 June 2017 | Volume 8 | Article 378
Pecze et al. Molecular Surgery Concept from Bench to Bedside
Karai, L., Brown, D. C., Mannes, A. J., Connelly, S. T., Brown, J., Gandal, M., et al.
(2004). Deletion of vanilloid receptor 1-expressing primary afferent neurons for
pain control. J. Clin. Invest. 113, 1344–1352. doi: 10.1172/JCI20449
Karai, L. J., Russell, J. T., Iadarola, M. J., and Olah, Z. (2004). Vanilloid
receptor 1 regulates multiple calcium compartments and contributes to Ca2+-
induced Ca2+ release in sensory neurons. J. Biol. Chem. 279, 16377–16387.
doi: 10.1074/jbc.M310891200
Kaszas, K., Keller, J. M., Coddou, C., Mishra, S. K., Hoon, M. A., Stojilkovic,
S., et al. (2011). Small molecule positive allosteric modulation of TRPV1
activation by vanilloids and acidic pH. J. Pharmacol. Exp. Ther. 340, 152–160.
doi: 10.1124/jpet.111.183053
Kedei, N., Szabo, T., Lile, J. D., Treanor, J. J., Olah, Z., Iadarola, M. J., et al. (2001).
Analysis of the native quaternary structure of vanilloid receptor 1. J. Biol. Chem.
276, 28613–28619. doi: 10.1074/jbc.M103272200
Kennedy, W. R., Vanhove, G. F., Lu, S. P., Tobias, J., Bley, K. R., Walk, D.,
et al. (2010). A randomized, controlled, open-label study of the long-term
effects of NGX-4010, a high-concentration capsaicin patch, on epidermal nerve
fiber density and sensory function in healthy volunteers. J. Pain 11, 579–587.
doi: 10.1016/j.jpain.2009.09.019
Kissin, E. Y., Freitas, C. F., and Kissin, I. (2005). The effects of intraarticular
resiniferatoxin in experimental knee-joint arthritis. Anesth. Analg. 101,
1433–1439. doi: 10.1213/01.ane.0000180998.29890.b0
Kissin, I., Davison, N., and Bradley, E. L. Jr. (2005). Perineural resiniferatoxin
prevents hyperalgesia in a rat model of postoperative pain. Anesth. Analg. 100,
774–780. doi: 10.1213/01.ANE.0000143570.75908.7F
Kosar, P. A., Naziroglu, M., Ovey, I. S., and Cig, B. (2016). Synergic effects of
doxorubicin and melatonin on apoptosis and mitochondrial oxidative stress in
MCF-7 breast cancer cells: involvement of TRPV1 channels. J. Membr. Biol.
249, 129–140. doi: 10.1007/s00232-015-9855-0
Kun, J., Helyes, Z., Perkecz, A., Ban, A., Polgar, B., Szolcsanyi, J., et al. (2012). Effect
of surgical and chemical sensory denervation on non-neural expression of the
transient receptor potential vanilloid 1 (TRPV1) receptors in the rat. J. Mol.
Neurosci. 48, 795–803. doi: 10.1007/s12031-012-9766-9
Lazar, J., Braun, D. C., Toth, A., Wang, Y., Pearce, L. V., Pavlyukovets, V.
A., et al. (2006). Kinetics of penetration influence the apparent potency of
vanilloids on TRPV1. Mol. Pharmacol. 69, 1166–11673. doi: 10.1124/mol.105.
019158
Lazzeri, M., Beneforti, P., and Turini, D. (1997). Urodynamic effects of intravesical
resiniferatoxin in humans: preliminary results in stable and unstable detrusor.
J. Urol. 158, 2093–2096. doi: 10.1016/s0022-5347(01)68164-3
Lebovitz, E. E., Keller, J. M., Kominsky, H., Kaszas, K., Maric, D., and Iadarola,
M. J. (2012). Positive allosteric modulation of TRPV1 as a novel analgesic
mechanism.Mol. Pain 8:70. doi: 10.1186/1744-8069-8-70
Li, S., Sun, Y., and Gao, D. (2013). Role of the nervous system in cancer metastasis.
Oncol. Lett. 5, 1101–1111. doi: 10.3892/ol.2013.1168
Liu, M., Liu, M. C., Magoulas, C., Priestley, J. V., and Willmott, N. J. (2003).
Versatile regulation of cytosolic Ca2+ by vanilloid receptor I in rat dorsal root
ganglion neurons. J. Biol. Chem. 278, 5462–5472. doi: 10.1074/jbc.m209111200
Lv, J., Qi, L., Yu, C., Yang, L., Guo, Y., Chen, Y., et al. (2015). Consumption of spicy
foods and total and cause specific mortality: population based cohort study.
BMJ 351:h3942. doi: 10.1136/bmj.h3942
Ma, F., Zhang, L., and Westlund, K. N. (2009). Reactive oxygen species mediate
TNFR1 increase after TRPV1 activation in mouse DRG neurons. Mol. Pain
5:31. doi: 10.1186/1744-8069-5-31
Mannes, A. J., Brown, D. C., Keller, J., Cordes, L., Eckenhoff, R. G., Caudle,
R. M., et al. (2005). Measurement of resiniferatoxin in serum samples by
high-performance liquid chromatography. J. Chromatogr. B Analyt. Technol.
Biomed. Life Sci. 823, 184–188. doi: 10.1016/j.jchromb.2005.06.042
Marshall, I. C., Owen, D. E., Cripps, T. V., Davis, J. B., McNulty, S., and Smart,
D. (2003). Activation of vanilloid receptor 1 by resiniferatoxin mobilizes
calcium from inositol 1,4,5-trisphosphate-sensitive stores. Br. J. Pharmacol.
138, 172–176. doi: 10.1038/sj.bjp.0705003
Masamoto, Y., Kawabata, F., and Fushiki, T. (2009). Intragastric administration
of TRPV1, TRPV3, TRPM8, and TRPA1 agonists modulates autonomic
thermoregulation in different manners in mice. Biosci. Biotechnol. Biochem. 73,
1021–1027. doi: 10.1271/bbb.80796
Michael Murphy, P. (2009). How mitochondria produce reactive oxygen species.
Biochem. J. 417, 1–13. doi: 10.1042/BJ20081386
Moesgaard, S. G., Brand, C. L., Sturis, J., Ahren, B., Wilken, M., Fleckner, J.,
et al. (2005). Sensory nerve inactivation by resiniferatoxin improves insulin
sensitivity in male obese Zucker rats. Am. J. Physiol. Endocrinol. Metab. 288,
E1137–E1145. doi: 10.1152/ajpendo.00356.2004
Moiseenkova-Bell, V. Y., Stanciu, L. A., Serysheva, I. I., Tobe, B. J., and Wensel, T.
G. (2008). Structure of TRPV1 channel revealed by electron cryomicroscopy.
Proc. Natl. Acad. Sci. U.S.A. 105, 7451–7455. doi: 10.1073/pnas.0711835105
Montell, C. (2005). The TRP superfamily of cation channels. Science’s
STKE: signal transduction knowledge environment. Sci. STKE 2005:re3.
doi: 10.1126/stke.2722005re3
Movsesyan, V. A., Stoica, B. A., Yakovlev, A. G., Knoblach, S. M., Lea, P. M. IV.,
Cernak, I., et al. (2004). Anandamide-induced cell death in primary neuronal
cultures: role of calpain and caspase pathways. Cell Death Differ. 11, 1121–1132.
doi: 10.1038/sj.cdd.4401442
Neubert, J. K., Karai, L., Jun, J. H., Kim, H. S., Olah, Z., and Iadarola, M.
J. (2003). Peripherally induced resiniferatoxin analgesia. Pain 104, 219–228.
doi: 10.1016/s0304-3959(03)00009-5
Neubert, J. K., Mannes, A. J., Keller, J., Wexel, M., Iadarola, M. J., and Caudle, R.
M. (2005). Peripheral targeting of the trigeminal ganglion via the infraorbital
foramen as a therapeutic strategy. Brain Res. Brain Res. Protoc. 15, 119–126.
doi: 10.1016/j.brainresprot.2005.05.003
Olah, Z., Josvay, K., Pecze, L., Letoha, T., Babai, N., Budai, D., et al. (2007). Anti-
calmodulins and tricyclic adjuvants in pain therapy block the TRPV1 channel.
PLoS ONE 2:e545. doi: 10.1371/journal.pone.0000545
Olah, Z., Szabo, T., Karai, L., Hough, C., Fields, R. D., Caudle, R. M.,
et al. (2001). Ligand-induced dynamic membrane changes and cell deletion
conferred by vanilloid receptor 1. J. Biol. Chem. 276, 11021–11030.
doi: 10.1074/jbc.M008392200
Park, Y. R., Chun, J. N., So, I., Kim, H. J., Baek, S., Jeon, J. H., et al. (2016). Data-
driven analysis of TRP channels in cancer: linking variation in gene expression
to clinical significance. Cancer Genomics Proteomics 13, 83–90. Available online
at: http://cgp.iiarjournals.org/content/13/1/83.long
Patapoutian, A., Tate, S., and Woolf, C. J. (2009). Transient receptor potential
channels: targeting pain at the source. Nat. Rev. Drug Discov. 8, 55–68.
doi: 10.1038/nrd2757
Payne, C. K., Mosbaugh, P. G., Forrest, J. B., Evans, R. J., Whitmore, K. E., Antoci,
J. P., et al. (2005). Intravesical resiniferatoxin for the treatment of interstitial
cystitis: a randomized, double-blind, placebo controlled trial. J. Urol. 173,
1590–1594. doi: 10.1097/01.ju.0000154631.92150.ef
Pecze, L., Blum, W., Henzi, T., and Schwaller, B. (2016a). Endogenous TRPV1
stimulation leads to the activation of the inositol phospholipid pathway
necessary for sustained Ca2+ oscillations. Biochim. Biophys. Acta 1863,
2905–2915. doi: 10.1016/j.bbamcr.2016.09.013
Pecze, L., Blum, W., and Schwaller, B. (2013). Mechanism of capsaicin receptor
TRPV1-mediated toxicity in pain-sensing neurons focusing on the effects of
Na+/Ca2+ fluxes and the Ca2+-binding protein calretinin. Biochim. Biophys.
Acta 1833, 1680–1691. doi: 10.1016/j.bbamcr.2012.08.018
Pecze, L., Josvay, K., Blum, W., Petrovics, G., Vizler, C., Olah, Z., et al. (2016b).
Activation of endogenous TRPV1 fails to induce overstimulation-based
cytotoxicity in breast and prostate cancer cells but not in pain-sensing neurons.
Biochim. Biophys. Acta 1863, 2054–2064. doi: 10.1016/j.bbamcr.2016.05.007
Pecze, L., Pelsoczi, P., Kecskes, M., Winter, Z., Papp, A., Kaszas, K., et al. (2009).
Resiniferatoxinmediated ablation of TRPV1+ neurons removes TRPA1 as well.
Can. J. Neurol. Sci. 36, 234–241. doi: 10.1017/S0317167100006600
Pecze, L., Szabo, K., Szell, M., Josvay, K., Kaszas, K., Kusz, E., et al.
(2008). Human keratinocytes are vanilloid resistant. PLoS ONE 3:e3419.
doi: 10.1371/journal.pone.0003419
Raisinghani, M., Pabbidi, R. M., and Premkumar, L. S. (2005). Activation of
transient receptor potential vanilloid 1 (TRPV1) by resiniferatoxin. J. Physiol.
567, 771–786. doi: 10.1113/jphysiol.2005.087874
Roh, E. J., Keller, J. M., Olah, Z., Iadarola, M. J., and Jacobson, K. A. (2008).
Structure-activity relationships of 1,4-dihydropyridines that act as enhancers
of the vanilloid receptor 1 (TRPV1). Bioorg. Med. Chem. 16, 9349–9358.
doi: 10.1016/j.bmc.2008.08.048
Shin, C. Y., Shin, J., Kim, B. M., Wang, M. H., Jang, J. H., Surh, Y. J., et al. (2003).
Essential role of mitochondrial permeability transition in vanilloid receptor
1-dependent cell death of sensory neurons. Mol. Cell. Neurosci. 24, 57–68.
doi: 10.1016/S1044-7431(03)00121-0
Frontiers in Physiology | www.frontiersin.org 10 June 2017 | Volume 8 | Article 378
Pecze et al. Molecular Surgery Concept from Bench to Bedside
Sterner, O., and Szallasi, A. (1999). Novel natural vanilloid receptor agonists: new
therapeutic targets for drug development. Trends Pharmacol. Sci. 20, 459–465.
doi: 10.1016/S0165-6147(99)01393-0
Szabo, T., Olah, Z., Iadarola, M. J., and Blumberg, P. M. (1999). Epidural
resiniferatoxin induced prolonged regional analgesia to pain. Brain Res. 840,
92–98. doi: 10.1016/S0006-8993(99)01763-1
Szallasi, A., and Blumberg, P. M. (1989). Resiniferatoxin, a phorbol-related
diterpene, acts as an ultrapotent analog of capsaicin, the irritant constituent
in red pepper. Neuroscience 30, 515–520. doi: 10.1016/0306-4522(89)90269-8
Szallasi, A., and Blumberg, P. M. (1992). Vanilloid receptor loss in rat sensory
ganglia associated with long term desensitization to resiniferatoxin. Neurosci.
Lett. 140, 51–54. doi: 10.1016/0304-3940(92)90679-2
Szallasi, A., and Blumberg, P. M. (1999). Vanilloid (Capsaicin) receptors and
mechanisms. Pharmacol. Rev. 51, 159–212.
Szallasi, A., Conte, B., Goso, C., Blumberg, P. M., and Manzini, S. (1993).
Characterization of a peripheral vanilloid (capsaicin) receptor in the
urinary bladder of the rat. Life Sci. 52, PL221–PL226. doi: 10.1016/0024-
3205(93)90051-4
Szallasi, A., Joo, F., and Blumberg, P. M. (1989). Duration of desensitization
and ultrastructural changes in dorsal root ganglia in rats treated with
resiniferatoxin, an ultrapotent capsaicin analog. Brain Res. 503, 68–72.
doi: 10.1016/0006-8993(89)91705-8
Szolcsanyi, J., Jancso-Gabor, A., and Joo, F. (1975). Functional and fine structural
characteristics of the sensory neuron blocking effect of capsaicin. Naunyn
Schmiedebergs. Arch. Pharmacol. 287, 157–169. doi: 10.1007/BF00510447
Szolcsanyi, J., Szallasi, A., Szallasi, Z., Joo, F., and Blumberg, P. M. (1990).
Resiniferatoxin: an ultrapotent selective modulator of capsaicin-sensitive
primary afferent neurons. J. Pharmacol. Exp. Ther. 255, 923–928.
Tender, G. C., Walbridge, S., Olah, Z., Karai, L., Iadarola, M., Oldfield, E.
H., et al. (2005). Selective ablation of nociceptive neurons for elimination
of hyperalgesia and neurogenic inflammation. J. Neurosurg. 102 522–525.
doi: 10.3171/jns.2005.102.3.0522
Tominaga, M., Caterina, M. J., Malmberg, A. B., Rosen, T. A., Gilbert, H., Skinner,
K., et al. (1998). The cloned capsaicin receptor integrates multiple pain-
producing stimuli. Neuron 21, 531–543. doi: 10.1016/s,0896-6273(00)80564-4
Touska, F., Marsakova, L., Teisinger, J., and Vlachova, V. (2011). A
“cute” desensitization of TRPV1. Curr. Pharm. Biotechnol. 12, 122–129.
doi: 10.2174/138920111793937826
van der Stelt, M., and Di Marzo, V. (2004). Endovanilloids. Eur. J. Biochem. 271,
1827–1834. doi: 10.1111/j.1432-1033.2004.04081.x
Watanabe, N., Horie, S., Michael, G. J., Spina, D., Page, C. P., and Priestley, J.
V. (2005). Immunohistochemical localization of vanilloid receptor subtype 1
(TRPV1) in the guinea pig respiratory system. Pulm. Pharmacol. Ther. 18,
187–197. doi: 10.1016/j.pupt.2004.12.002
Zagotta, W. N., Gordon, M. T., Senning, E. N., Munari, M. A., and Gordon, S. E.
(2016). Measuring distances between TRPV1 and the plasma membrane using
a noncanonical amino acid and transition metal ion FRET. J. Gen. Physiol. 147,
201–216. doi: 10.1085/jgp.201511531
Conflict of Interest Statement: ZO is named as an inventor, but not the owner of a
patent #US8338457 B2 related to this study. Otherwise, the authors declare that the
research was conducted in the absence of any commercial or financial relationships
that could be construed as a potential conflict of interest.
Copyright © 2017 Pecze, Viskolcz and Oláh. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Physiology | www.frontiersin.org 11 June 2017 | Volume 8 | Article 378
